Research and Markets (http://www.researchandmarkets.com/research/963952b8/chronic_myelocytic) has announced the addition of Global Markets Direct's new report "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2012" to their offering.
Global Markets Direct's, 'Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2012', provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) therapeutic pipeline. This report provides information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia). 'Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Key Topics Covered:
- Introduction
- Global Markets Direct Report Coverage
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Overview
- Therapeutics Development
- An Overview of Pipeline Products for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics under Development by Companies
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics - Products under Development by Companies
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics - Products under Investigation by Universities/Institutes
- Companies Involved in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics Development
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics - Drug Profile Updates
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics - Discontinued Products
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics - Dormant Products
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
Companies Mentioned:
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Amgen Inc.
- Merck & Co., Inc.
- Gamida Cell Ltd.
- Bio-Path Holdings, Inc.
- BioSante Pharmaceuticals, Inc.
- Novartis AG
- Cephalon, Inc.
- Nippon Shinyaku Co., Ltd.
- Pfizer Inc.
- Celgene Corporation
- Incyte Corporation
- AEterna Zentaris Inc.
- Ariad Pharmaceuticals, Inc.
- TopoTarget A/S
- Threshold Pharmaceuticals, Inc.
- Synta Pharmaceuticals Corp.
- Natco Pharma Limited
- Simcere Pharmaceutical Group
- Piramal Life Sciences Limited
- SymBio Pharmaceuticals Limited
- ViroStatics, srl
- S-BIO Pte Ltd
- Deciphera Pharmaceuticals, LLC
- Stemline Therapeutics, Inc.
- Onconova Therapeutics, Inc
- Syndax Pharmaceuticals, Inc.
- Globeimmune, Inc.
- KaloBios Pharmaceuticals, Inc.
- Aprea AB.
- Targa Therapeutics Corp.
For more information visit http://www.researchandmarkets.com/research/963952b8/chronic_myelocytic
Source: Global Markets Direct